Pages that link to "Q83304081"

The following pages link to Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy (Q83304081):

Displaying 21 items.

• Low-dose rate brachytherapy for men with localized prostate cancer (Q24235544) (← links)
• Systematizing support in cessation smoking to improve care for cancer patients (Q26745535) (← links)
• Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies (Q34267991) (← links)
• Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis (Q34976375) (← links)
• Permanent prostate seed brachytherapy: a current perspective on the evolution of the technique and its application (Q37024510) (← links)
• Brachytherapy with permanent seed implantation (Q37028932) (← links)
• 125Iodine monotherapy for Japanese men with low- and intermediate-risk prostate cancer: outcomes after 5 years of follow-up (Q37632568) (← links)
• A critical analysis of the long-term impact of brachytherapy for prostate cancer: a review of the recent literature (Q37839653) (← links)
• Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care? (Q38015028) (← links)
• The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support (Q38273676) (← links)
• American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review. (Q39006967) (← links)
• Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions (Q39626881) (← links)
• Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants (Q41829621) (← links)
• Outcomes of Gleason Score ≤ 8 among high risk prostate cancer treated with 125I low dose rate brachytherapy based multimodal therapy (Q41955736) (← links)
• Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer (Q44929926) (← links)
• Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer (Q45128593) (← links)
• Cancer de la prostate (Q57566962) (← links)
• Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification (Q64101096) (← links)
• Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation (Q82609374) (← links)
• Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer (Q83235755) (← links)
• High-Risk Prostate Cancer With Gleason Score 8–10 and PSA Level ≤15 ng/ mL Treated With Permanent Interstitial Brachytherapy (Q85173927) (← links)